Presented at: Jefferies 2015 Global Healthcare Conference

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Presented at: Jefferies 2015 Global Healthcare Conference"

Transcription

1 Presented at: Jefferies 2015 Global Healthcare Conference

2 Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution 6 Strategic Alliances & Growth Plan 7 Value Proposition Putting Science to Work 2

3 Introduction India s Largest CRO Integrated Discovery, Development & Manufacturing Platform Small & Large Molecules, ADCs, Oligonucleotides Shareholding Pattern Listed on NSE & BSE Market Cap: ~ USD 1 Bn India s 1 st Listed CRO Global Clientele Servicing 221+ clients globally Clients across Pharma, Biotech, Speciality Chemicals, Cosmetics etc. 3

4 A View of the Site End-to-end discovery and development from a single site 4

5 Who We Are Today: A Global High Growth CRO Company 21+ years of unparalleled experience Strong Growth and Profitability Discovery & Development, Clinical development and manufacturing services for small molecules & biologics Focus on novel molecular entities 2,200+ highly experienced multi-disciplinary scientific team Quality driven organization with excellent track record World-class R&D and manufacturing infrastructure spread over 900,000 sq. ft. Impeccable track record in confidentiality & intellectual property since inception Customized and adaptive models FY 2011 FY 2012 FY 2013 FY 2014 FY 2015 Revenue (USD Mn) EBITDA (USD Mn) 5

6 Established Integrated Service Platforms Discovery Chemistry Development Drug Substance Development Manufacturing Clinical Supplies Small Molecules Large Molecules Biology Integrated drug discovery Therapeutic Antibody Discovery & Engineering; Cell Line Development Drug Product Development Integrated Drug Substance Drug Product Clinical Services (India) Allied Services Specialty Molecules Commercial Supplies Bioprocess Development Process Characterisation Clinical Manufacturing (Microbial & Mammalian) Wide Spectrum of Services Across a Range of Molecules Including Antibody-Drug Conjugates and Oligonucleotides 6

7 End-to-End Integrated Capabilities Providing Clients With Multiple Entry Points Discovery Development Commercialisation Target Identification Target Validation Lead Generation Target Optimisation Lead Selection Preclinical Animal Safety Ph I Clinical Ph II API and Drug product Development Ph III Drug filing with FDA & other global regulatory authorities Product launch Manufacture Marketing/ Phase IV Syngene offers an integrated Service Platform for both small and large molecules 7

8 Adaptability & Scalability Proven Track Records 1 FTE FTEs Lab scale supplies Clinical supplies of NCEs /biologics Adequate scale & capacity Start-up / virtual companies Dedicated areas to customers Customized project management support Global pharma/ biotech companies Dedicated Centres-of-Excellence Establishing Governance Model for strategic collaborations Track record of Customer retention Operational efficiencies Centralized project management team Start small track record to think big and deliver big 8

9 Expansion Plans # Capex Investment Area Key Highlight Operational by Discovery, Development & Associated GMP Operations 1 Syngene Research Centre State-of-the art R&D centre supporting integrated programs 1H Formulation Centre Late Stage & Commercial Manufacturing 3 Commercial chemical API Manufacturing 4 Biologics Manufacturing Other Services & New Capabilities OSD, Parenteral, liquid oral & semi solid formulations (Development & early clinical) Commercial manufacturing of NCEs & advanced intermediates Commercial-scale manufacturing for antibodies & other mammalian culture products 2H H H New capabilities Oligonucleotide facility, ADC facility, viral testing lab Staggered Investments to be funded by Internal Accruals 9 Investment of up to $200 Mn in our facilities over FY16 to FY18

10 Syngene Research Centre Building State-of-the art R&D centre Supporting increasing demands providing integrated discovery & development programs Operational in 1H

11 Best Practices R&D and Manufacturing Infrastructure Conform with international accreditations Focus on Quality Quality certified processes and instruments Intellectual Property Protection Strong IP and confidentiality procedures Global Standards Scientist Talent Ability to attract global scientist talent 11

12 World-class R&D & Manufacturing Facilities Over 900,000 sq. ft. of labs and manufacturing facilities USD 165 Mn (1) total tangible fixed assets (gross block) Key accreditations USFDA audited EMA audited End-to-end discovery and development services on a single platform OHSAS 8001 ISO Operate to standards that are consistent with large global clients Successful audits by global regulators Intention to evolve from a CRO into a CRAMS GLP Certificate ISO AAALAC Accredited Infrastructure Qualified to Meet International Standards 12 (1) As of September 30, 2015

13 Talented and Qualified Pool of Scientists Densest cluster of scientists in the country 85% of scientists with a Masters/Doctorate in Science Global talent - significant no. of senior management is US/ EU trained Others 15% Ph.Ds. 11% Recruitment from top International and Indian research institutions High retention rate HR management philosophy - hire-train-retain 2,153 (1) scientists Master's Degree 74% Highly Experienced and Qualified Team of Scientists has Helped Syngene Create a Competitive Edge over its Peers 13 (1) As of September 30, 2015

14 Attractive Blue Chip Customer Base Highly successful track-record in molecule development Client base includes 8 of the top 10 global pharma company by 2014 sales (1) 8 of our top 10 clients have been associated for more than 5 years illustrating their longstanding and extensive relationship Services to 221 Clients (FY15) across diverse sectors Pharma Biotech Nutrition 71% of FY15 revenue from top 10 customers compared to 79% in FY (1) Top 10 pharmaceuticals companies are by sales for 2014 as per IMS Health Midas, December Animal Health Specialty Chemicals Agro Chemicals

15 Flexible Business Model to Serve a Wide Client Base Extend Expand Engage Component plays Cluster plays Full Time Equivalent (FTE) + Fee For Service (FFS) Integrated play Dedicated play Dedicated Centers 15

16 Dedicated Centres Largest R&D Centre in Asia for BMS (2009). Contract extended till Dedicated centre of research excellence with world class facilities. Over 400 scientists supporting Novel Molecule research in small and large molecules. Produced nine drug candidates for further study and advanced new compounds for first-in-human studies. Dedicated research centre in India for Baxter (2013). State of the art facility supporting R&D of medical products and devices worldwide. Engages a multidisciplinary team of c.150 scientists. R&D activities centred on product and analytical development, preclinical evaluation in parenteral nutrition and renal therapy. Abbott Nutrition s 1st R&D centre in India set up in collaboration with Syngene (2012). Dedicated research centre supporting development of affordable, nutrition products. c.30 multi-disciplinary scientists engaged in product development lifecycle. Focus on maternal, pediatric, neo-natal nutrition and diabetes care in line with emerging market needs. 16

17 Strong Track Record Of Topline Growth Growth driven by increase in sales from existing clients and acquisition of new clients Total Revenue (USD Mn) 143 Engage, expand and extend strategy to extend client relationship over a longer period of time Growth in total number of clients Increase in average revenue from largest clients Increase in number of services offered to clients FY 2011 FY 2012 FY 2013 FY 2014 FY 2015 H1 FY

18 Value Proposition Putting Science to Work World class infrastructure and systems Quality systems global compliance Strong scientific team Global mindset and standards Data protection & confidentiality IP assured and client owned Affordable Innovation 18

19 THANK YOU

An integrated global healthcare company

An integrated global healthcare company An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment

More information

Life Science - a sustainable platform for profitable growth

Life Science - a sustainable platform for profitable growth Life Science - a sustainable platform for profitable growth 2012 Life Science Information Day Bernd Reckmann Member of the Executive Board and Head of Chemicals Molsheim, France - December 5, 2012 Agenda

More information

BIOMEDICAL SCIENCES INDUSTRY IN SINGAPORE ROLE OF EDB

BIOMEDICAL SCIENCES INDUSTRY IN SINGAPORE ROLE OF EDB BIOMEDICAL SCIENCES INDUSTRY IN SINGAPORE ROLE OF EDB JAN 2014 1 Singapore s Economic Journey GDP (US$B) 260 240 220 200 180 160 140 120 100 80 60 40 20 0 1960-1969 Labour Intensive 1970 1979 Skill Intensive

More information

Can India be the Leader in Global Generics. Rtn. J. Jayaseelan.,B.Pharm., M.B.A., Managing Director

Can India be the Leader in Global Generics. Rtn. J. Jayaseelan.,B.Pharm., M.B.A., Managing Director Can India be the Leader in Global Generics Rtn. J. Jayaseelan.,B.Pharm., M.B.A., Managing Director Indian Pharma Industry Before 1970 Depending on MNC from USA and Europe for supply of Medicines Hardly

More information

Alliance4U - The collaboration initiative to move drug candidates forward

Alliance4U - The collaboration initiative to move drug candidates forward - The collaboration initiative to move drug candidates forward Introduction What are we offering? How? Why apply? Terms Background For grant applications and to attract venture capital start-up companies

More information

ACETO Corporation Investor Presentation November 2, 2016

ACETO Corporation Investor Presentation November 2, 2016 NASDAQ:ACET ACETO Corporation Investor Presentation November 2, 2016 Sourcing & Supplying Quality Products Worldwide Disclosure This presentation contains forward-looking statements, as defined by the

More information

Company Presentation

Company Presentation Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars

More information

Open Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum

Open Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities

More information

NEW CHEMICAL ENTITIES

NEW CHEMICAL ENTITIES NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product

More information

Introduction to the Healthcare Continuum

Introduction to the Healthcare Continuum Capital Markets Day Introduction to the Healthcare Continuum Richard Ridinger, CEO Capital Markets Day Introduction to the Healthcare Continuum, Richard Ridinger, 27 October 2016 Additional Information

More information

Brand Quality with Asian Advantages

Brand Quality with Asian Advantages Brand Quality with Asian Advantages ScinoPharm Taiwan, Ltd. No.1, Nan-Ke 8th Road, Tainan Science Park, Shan-Hua, Tainan, 74144, Taiwan TEL : 886-6-505-2888 FAX : 886-6-505-2898 Email Contact : mkt@scinopharm.com

More information

DPP - DSM in motion: driving focused growth DSM and JLL create leading pharma services company in US$ 2.6bn transaction 19 November 2013.

DPP - DSM in motion: driving focused growth DSM and JLL create leading pharma services company in US$ 2.6bn transaction 19 November 2013. DPP - DSM in motion: driving focused growth DSM and JLL create leading pharma services company in US$ 2.6bn transaction 19 November 2013 Page Safe harbor statement This presentation may contain forward-looking

More information

BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma

BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma 2 Novozymes solutions dedicated to the biopharmaceutical industry

More information

EVT Execute & EVT Innovate Leading drug discovery

EVT Execute & EVT Innovate Leading drug discovery EVT Execute & EVT Innovate Leading drug discovery Evotec AG, Nine-month 2015 Interim Report, 10 November 2015 Forward-looking statements Information set forth in this presentation contains forward-looking

More information

PharmaceuticalDevelopment

PharmaceuticalDevelopment PharmaceuticalDevelopment Activities & Timelines Agenda Factors driving development Types of product Timelines for development Factors affecting length of development Regulation of Pharma environment Cost

More information

Catalent Biologics & Clinical Supplies The SMART Solution

Catalent Biologics & Clinical Supplies The SMART Solution Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany

More information

BIOTECHNOLOGY. Bouvé College of Health Sciences College of Science. Networked for Success. Networked for Industry. Networked for Life.

BIOTECHNOLOGY. Bouvé College of Health Sciences College of Science. Networked for Success. Networked for Industry. Networked for Life. MASTER OF SCIENCE BIOTECHNOLOGY Networked for Success. Networked for Industry. Networked for Life. Bouvé College of Health Sciences College of Science Northeastern s Biotechnology Masters program synthesizes

More information

Valentina Gualato, Ph.D. Process Development Scientist

Valentina Gualato, Ph.D. Process Development Scientist COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing

More information

PIRAMAL DISCOVERY SOLUTIONS

PIRAMAL DISCOVERY SOLUTIONS PIRAMAL DISCOVERY SOLUTIONS Pharma Solutions products and services Delivering Globally Integrated Solutions across the drug lifecycle We are the Contract Development & Manufacturing arm of Piramal Healthcare,

More information

SERVICES FOR. Devices and Combination Products

SERVICES FOR. Devices and Combination Products SERVICES FOR Devices and Combination Products How to Contact Us U.S. FACILITIES / CLIENT SERVICES St. Paul 2540 Executive Drive St. Paul, MN 55120 FAX 651.675.2005 Atlanta 1265 Kennestone Circle Marietta,

More information

Avacta Group plc! Innovation for global health! Interim Results! 25th April 2012!

Avacta Group plc! Innovation for global health! Interim Results! 25th April 2012! Avacta Group plc Innovation for global health Interim Results 25th April 2012 Important Notice This presentation does not constitute a recommendation regarding the shares of Avacta Group plc (the Company

More information

Merck Strategy. Richard T. Clark Chief Executive Officer and President

Merck Strategy. Richard T. Clark Chief Executive Officer and President Merck Strategy Richard T. Clark Chief Executive Officer and President The Global Health Care Market is Challenging but Creates Great Opportunity for Merck Challenges Declining success rates in new drug

More information

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services

More information

Photocure ASA. Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO

Photocure ASA. Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Brilliance in photodynamic technology TM Photocure ASA Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Agreement with Salix

More information

EVT Execute & EVT Innovate World-class drug discovery

EVT Execute & EVT Innovate World-class drug discovery EVT Execute & EVT Innovate World-class drug discovery Evotec AG, First Quarter Report 2015, 12 May 2015 Forward-looking statements Information set forth in this presentation contains forward-looking statements,

More information

Orphan Pharma: pathfinders for an increasingly specialised industry

Orphan Pharma: pathfinders for an increasingly specialised industry Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty

More information

Drug Discovery in China

Drug Discovery in China Drug Discovery in China Media Visit to Roche in China Shanghai 30 October 2005 Li Chen, Ph. D. Head of Research, Chief Scientific Officer Roche R&D Center (China) Ltd. Research Business Model in China

More information

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet Dalvir Gill, PhD - Chief Executive Officer 17 October, 2014 Presentation Objectives + TransCelerate History + Participating

More information

Bringing Biotech and Specialty Chemical Expertise to Our Customers

Bringing Biotech and Specialty Chemical Expertise to Our Customers Corporate Pharma&Biotech Bringing Biotech and Specialty Chemical Expertise to Our Customers Richard Ridinger CEO Lonza Corporate Additional Information and Disclaimer Lonza Group Ltd has its headquarters

More information

A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program

A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry CLEANING VALIDATION Instructors Loh Kean Chong Rick Ng Date and Time

More information

Our passion is to deliver sustainable value to our customers 2007 First Half Results 26 July 2007

Our passion is to deliver sustainable value to our customers 2007 First Half Results 26 July 2007 Our passion is to deliver sustainable value to our customers 2007 First Half Results 26 July 2007 Toralf Haag Chief Financial Officer Disclaimer Certain matters discussed in this presentation may constitute

More information

Multitude of opportunities for Finnish pharmaceutical industry in India

Multitude of opportunities for Finnish pharmaceutical industry in India 1 Multitude of opportunities for Finnish pharmaceutical industry in India Dr. Esa Heinonen, MD, PhD Senior Advisor Business Development and Support Orion Pharma 2 3 Challenges of pharmaceutical industry

More information

An Exclusive Interview with Dr Jan-Anders Karlsson

An Exclusive Interview with Dr Jan-Anders Karlsson Dr Jan-Anders Karlsson took over the helm as the CEO of S*BIO from January 2005. He has extensive experience in the pharmaceutical industry, with many proven successes in the drug discovery area. Dr Karlsson

More information

UK- India Science Bridge: BioPharm 2020

UK- India Science Bridge: BioPharm 2020 DST INDIA - RESEARCH COUNCILS UK UK- India Science Bridge: BioPharm 2020 Entrepreneurial Opportunities for Indian and UK Scientists in the Pharmaceutical and Biotechnology Industries UK-India Impact Symposium

More information

DISCUSSION SUMMARY. Q3 & 9M FY16 Results Highlights. Consolidated Financials. About Us. Business Strategy & Outlook

DISCUSSION SUMMARY. Q3 & 9M FY16 Results Highlights. Consolidated Financials. About Us. Business Strategy & Outlook DISHMAN PHARMACEUTICALS & CHEMICALS LIMITED Q3 & 9M FY16 RESULTS UPDATE FEBRUARY 2016 DISCUSSION SUMMARY Q3 & 9M FY16 Results Highlights Consolidated Financials About Us Business Strategy & Outlook 2 SAFE

More information

Job Opportunities at the Cell Therapy Catapult

Job Opportunities at the Cell Therapy Catapult Job Opportunities at the Cell Therapy Catapult The Cell Therapy Catapult is a centre of excellence for regenerative medicine. Its vision is for the UK to be a global leader in the development, delivery

More information

Healthcare Innovation in the UK - A Royal Society of Chemistry Position Paper

Healthcare Innovation in the UK - A Royal Society of Chemistry Position Paper Healthcare Innovation in the UK - A Royal Society of Chemistry Position Paper Introduction The pharmaceutical industry (Pharma) has made important contributions to quality of life, longevity, economic

More information

Pharmaceutical Quality Management System: Current Concept

Pharmaceutical Quality Management System: Current Concept Pharmaceutical Quality Management System: Current Concept Neetu Dubey 1, *, Himanshu Gupta 3, R.K. Sharma 2, Nitin Dubey 1, Nidhi Dubey 4 1. IPS Academy, Indore, Madhya Pradesh, India. 2. Prestige Institute

More information

Transforming relationships Unleashing innovation

Transforming relationships Unleashing innovation Transforming relationships Unleashing innovation Translating Discoveries Into Products A model for innovation driven economic growth Barbara Handelin, PhD 1 The Innovation Gap Economic Opportunity Industries

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

STATS WINDOW. INDUSTRY REVIEW AT A GLANCE Global Pharmaceutical Industry

STATS WINDOW. INDUSTRY REVIEW AT A GLANCE Global Pharmaceutical Industry Volume 6, Issue 6, December 2013 STATS WINDOW The Pacific Business Review International has taken an initiative to start a section which will provide a snapshot of major Global & Indian economic indicators

More information

DZIF-Product Development Unit (PDU)

DZIF-Product Development Unit (PDU) November 29, 2013 7 th International VPM Days DZIF-Product Development Unit (PDU) - DZIF-TPMO at HZI - DZIF-OSRA at PEI Thomas Hesterkamp, Helmholtz Zentrum für Infektionsforschung Support from TPMO &

More information

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010 U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction

More information

VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH

VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH Lucia Faccio, Direttore Sviluppo Ricerca Fondazione Telethon Why should academia transfer

More information

Anforderungen der Life-Science Industrie an die Hochschulen. Hans Widmer Novartis Institutes for BioMedical Research

Anforderungen der Life-Science Industrie an die Hochschulen. Hans Widmer Novartis Institutes for BioMedical Research Anforderungen der Life-Science Industrie an die Hochschulen Hans Widmer Novartis Institutes for BioMedical Research There s nothing more extraordinary than a normal life 2 What does industry expect from

More information

Guide to submitting your small molecule or therapeutic antibody target

Guide to submitting your small molecule or therapeutic antibody target Guide to submitting your small molecule or therapeutic antibody target Background on MRC Technology Understanding the application review process What MRC Technology looks for in a therapeutic antibody

More information

accreditation will it still be needed or will other schemes show up?

accreditation will it still be needed or will other schemes show up? By Leif Madsen, DELTA, President of Eurolab Denmark Member of ISO WG 44 We re facing the revision of ISO 17025, that may entail significant changes in how the laboratories are operated. Other developments

More information

The Biotech Business Life Cycle. The Lawyer s Role as Counselor and Advisor

The Biotech Business Life Cycle. The Lawyer s Role as Counselor and Advisor The Biotech Business Life Cycle and The Lawyer s Role as Counselor and Advisor ASU February 15, 2010 1 BIOTECH BUSINESS CYCLE AN INTERDISCIPLINARY APPROACH TO LEGAL REPRESENTATION Intellectual Property

More information

RECIPHARM TAKES NEXT STEP TOWARDS GLOBAL LEADERSHIP 18 th April, 2016 Thomas Eldered, Jean-François Hilaire

RECIPHARM TAKES NEXT STEP TOWARDS GLOBAL LEADERSHIP 18 th April, 2016 Thomas Eldered, Jean-François Hilaire RECIPHARM TAKES NEXT STEP TOWARDS GLOBAL LEADERSHIP 18 th April, 2016 Thomas Eldered, Jean-François Hilaire 1 RECIPHARM TAKES NEXT STEP TOWARDS GLOBAL LEADERSHIP Another step change in reach and scale

More information

GMP Pharma BV. Netherlands

GMP Pharma BV. Netherlands GMP Pharma BV Netherlands Connecting the European & Indian Pharmaceutical, Biotechnology and Biopharmaceutical Industry for parallel growth and solicitation. About Us: GMP Pharma BV is a multisource organization

More information

Avg cost of a complex trial $100mn. Avg cost per patient for a Phase III Study

Avg cost of a complex trial $100mn. Avg cost per patient for a Phase III Study 1 Industry Perspective Over the last several years, clinical research costs have sky rocketed while new drug approvals are at multi-year lows. Studies have become global in nature and more complex to manage

More information

Kelley Executive Certificate in the Business of Life Sciences Is this your year to move ahead?

Kelley Executive Certificate in the Business of Life Sciences Is this your year to move ahead? Kelley Executive Certificate in the Business of Life Sciences Is this your year to move ahead? TAILORED TO THE INDUSTRY FLEXIBLE BUT CONSISTENT UNIQUE DELIVERY CROSS INDUSTRY NETWORKING THE ECBLS MEANS

More information

Eudendron: an Innovative Biotech Start-up

Eudendron: an Innovative Biotech Start-up Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description

More information

Technology and Expertise Add Operational Value to Medical Device Trials

Technology and Expertise Add Operational Value to Medical Device Trials Technology and Expertise Add Operational Value to Medical Device Trials Copyright 2015 Medidata Solutions. Medidata Solutions and other trademarks reserved in the US and globally. Medidata and other marks

More information

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened

More information

Making the most of academic drug target discoveries

Making the most of academic drug target discoveries Making the most of academic drug target discoveries Richard Reschen, Isis Innovation, University of Oxford The explosion of new technologies and research techniques, and encouragement from funding agencies

More information

A leader in the development and application of information technology to prevent and treat disease.

A leader in the development and application of information technology to prevent and treat disease. A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today

More information

Marieme Ba for CAAST-NET + 1 st stakeholder meeting Entebbe November 2014

Marieme Ba for CAAST-NET + 1 st stakeholder meeting Entebbe November 2014 Coming together is a beginning, keeping together is progress, working together is success. - Henry Ford - Considering the clinical research industry as an area for enhanced public-private sector collaboration

More information

Working with ICH Quality Guidelines - the Canadian Perspective

Working with ICH Quality Guidelines - the Canadian Perspective Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction

More information

Key Findings. Use this report to... The Top 10 Contract Research Organizations

Key Findings. Use this report to... The Top 10 Contract Research Organizations Key Findings The global CRO industry valued $18bn in 2008, an increase of 14% over 2007. The CRO market will grow at an annual rate of 14% over the 2009 13 period. Quintiles leads the global CRO market

More information

Lonza Reports Record First Quarter

Lonza Reports Record First Quarter Pharma&Biotech Lonza Reports Record First Quarter Q1 2016 Qualitative Business Update 26 April 2016 Richard Ridinger CEO Lonza Additional Information and Disclaimer Lonza Group Ltd has its headquarters

More information

Dear Business Development or Corporate Alliance Director/Manager,

Dear Business Development or Corporate Alliance Director/Manager, Korea Drug Research Association(KDRA) and Korea Health Industry Development Institute(KHIDI) cordially request the potential global outsourcing partners(cros, CMOs, CSOs & Consulting Firms) having contract

More information

From Research Services and Process Development to GMP Manufacturing

From Research Services and Process Development to GMP Manufacturing From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development

More information

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations

More information

Biomedical Accelerator Fund. Office of Technology Development Harvard University

Biomedical Accelerator Fund. Office of Technology Development Harvard University Biomedical Accelerator Fund Office of Technology Development Harvard University Curtis Keith, Chief Scientific Officer May 21, 2012 Mission of Harvard s Office 2 Organizational Structure of Harvard OTD

More information

Healthcare Solid performance, strong perspectives Siemens Capital Market Day Berlin, December 9, 2014

Healthcare Solid performance, strong perspectives Siemens Capital Market Day Berlin, December 9, 2014 Hermann Requardt Member of the Managing Board & Healthcare CEO Healthcare Solid performance, strong perspectives Siemens Capital Market Day Notes and forward-looking statements This document contains statements

More information

Regulatory Submission: Applying GLP in Surgical Efficacy Studies

Regulatory Submission: Applying GLP in Surgical Efficacy Studies Regulatory Submission: Applying GLP in Surgical Efficacy Studies Curtis Schondelmeyer, DVM Director Preclinical Veterinary Services and Efficacy and Surgical Research Services Welcome to Toxikon 2 CONFIDENTIAL

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

IMI2: why, what, how?

IMI2: why, what, how? IMI2: why, what, how? The Right prevention and treatment, to the right patient, at the right time Isabelle Thizon-de Gaulle VP, Strategic initiatives & Scientific relations Sanofi R&D Innovative Medicines

More information

Building innovative drug discovery alliances. Profitable. Growth Go

Building innovative drug discovery alliances. Profitable. Growth Go Building innovative drug discovery alliances Innovation n & Profitable Growth Go Evotec AG, H1 Presentation, 8 th August 2012 Forward-looking statements Information set forth in this presentation contains

More information

GenScript USA Incorporation:

GenScript USA Incorporation: New Jersey with a subsidiary site in Nanjing, China. Our dedication to innovation has led GenScript to generate a continuous flow of services and products to ease and Job ID: NJ001 Position: Head of Animal

More information

exactly. The need for efficiency in developing effective new therapeutics has never been greater.

exactly. The need for efficiency in developing effective new therapeutics has never been greater. exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,

More information

Biotechpharma company profile

Biotechpharma company profile Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing

More information

www.hcltech.com Clinical Platform Compliance in the Cloud

www.hcltech.com Clinical Platform Compliance in the Cloud www.hcltech.com Clinical Platform Compliance in the Cloud Application Services and Infrastructure HCL s Clinical Platform as a Service (CPaaS) is the first GxP compliant clinical information management

More information

UDG Healthcare plc An International Healthcare Services Organisation

UDG Healthcare plc An International Healthcare Services Organisation UDG Healthcare plc An International Healthcare Services Organisation Jefferies 2014 Global Healthcare Conference 2014 Liam FitzGerald, CEO 20 November 2014 1 FORWARD LOOKING STATEMENTS Some statements

More information

A vaccine for rheumatoid arthritis

A vaccine for rheumatoid arthritis A vaccine for rheumatoid arthritis Professor Ranjeny Thomas Founder and Director of Dendright Pty Limited Head, Autoimmunity Division, Diamantina Institute, The University of Queensland About Dendright

More information

WHITE PAPER. Optimizing Drug Registration in China: Category I Route

WHITE PAPER. Optimizing Drug Registration in China: Category I Route WHITE PAPER Optimizing Drug Registration in China: Category I Route ppdi.com April 2013 EXECUTIVE SUMMARY With a population of 1.3 billion and a pharmaceutical market growing at nearly 20 percent per year,

More information

Pharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success

Pharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success Pharmaceuticals Production Services Boehringer Ingelheim Our expertise in world-class contract manufacturing for your success Successful partnership Dr Wolfram Carius Head of Corporate Division Pharmaceuticals

More information

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more: www.aaps.org/forstudents

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more: www.aaps.org/forstudents Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

Press Release. iphex 2013 to showcase on Indian pharma exports; R & D capabilities

Press Release. iphex 2013 to showcase on Indian pharma exports; R & D capabilities Press Release iphex 2013 to showcase on Indian pharma exports; R & D capabilities Pharmexcil s iphex 2013 for global showcasing of Indian Pharma products Over 400 international buyers and regulators expected

More information

Read the Questions Carefully

Read the Questions Carefully PHT. 463- (Quality Control of Pharmaceutical Dosage Forms) Midterm Exam I Dr. Ibrahim A. Alsarra s Section Part I Read the Questions Carefully TRUE OR FALSE: Indicate whether the statement is true or false

More information

NORTH CAROLINA STATE UNIVERSITY NORTH CAROLINA STATE UNIVERSITY Office of Technology Transfer

NORTH CAROLINA STATE UNIVERSITY NORTH CAROLINA STATE UNIVERSITY Office of Technology Transfer NORTH CAROLINA STATE UNIVERSITY Office of Technology Transfer putting ideas to work March 2007 Dr. Rob Whitehead Associate Director, Office of Technology Transfer March 2008 Research Extensive, Land-grant

More information

Introduction to Enteris BioPharma

Introduction to Enteris BioPharma Introduction to Enteris BioPharma Enteris BioPharma Intelligent Solutions for Oral Drug Delivery Privately held, New Jersey based biotech company Owned solely by Victory Park Capital, a large Chicago based

More information

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life

More information

QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES

QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate

More information

From The Lab To Your Medicine Cabinet:

From The Lab To Your Medicine Cabinet: From The Lab To Your Medicine Cabinet: A Pharmaceutical Drug s Journey Presented by: Dr. Steven Hansel Sr. Director; Pfizer Moderated by: Sam Gilchrist Ph.D. Candidate; UBC The Drug Development Process

More information

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity

More information

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey The pharmaceutical

More information

Industry Insight - Indian Biopharma

Industry Insight - Indian Biopharma Brochure More information from http://www.researchandmarkets.com/reports/2043221/ Industry Insight - Indian Biopharma Description: Biopharmaceuticals are complex macromolecules (Large molecules) created

More information

An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore

An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore A CanBiotech Report CanBiotech, 2007 1 An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight

More information

New Advances in Cancer Treatments. March 2015

New Advances in Cancer Treatments. March 2015 New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

April, Investor Presentation

April, Investor Presentation April, 2016 Investor Presentation 2 Safe Harbor Certain statements in this presentation concerning our future growth prospects are forward-looking statements regarding our future business expectations

More information

Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation

Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Industry Studies Association Pittsburgh, June 1, 2011 Elisabeth Reynolds, Ph.D.

More information

West Nile Virus Infections-Pipeline Insights, 2016

West Nile Virus Infections-Pipeline Insights, 2016 Brochure More information from http://www.researchandmarkets.com/reports/3533615/ West Nile Virus Infections-Pipeline Insights, 2016 Description: West Nile Virus Infections-Pipeline Insights, 2016 provides

More information

Triskel: a strategic consulting firm for biopharmaceutical companies

Triskel: a strategic consulting firm for biopharmaceutical companies BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland

More information

The Aptuit Center for Drug Discovery & Development Verona, Italy. Uncommon Expertise. Exceptional Results.

The Aptuit Center for Drug Discovery & Development Verona, Italy. Uncommon Expertise. Exceptional Results. The Aptuit Center for Drug Discovery & Development Verona, Italy Uncommon Expertise. Exceptional Results. 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise,

More information

Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics

Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics John D Antonio Practice Leader, Licensing & Competitive Intelligence About Paragon We help increase asset value from

More information

Table of Contents. Presented by

Table of Contents. Presented by Improving Markets, Services, and Technologies Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com

More information